 Lisa Kosmiski
Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Energy Metabolism | 7 | 2013 | 762 | 1.400 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 6 | 2012 | 18 | 1.250 |
Why?
| | HIV Infections | 12 | 2012 | 2454 | 1.200 |
Why?
| | Rest | 3 | 2013 | 104 | 0.930 |
Why?
| | Lipodystrophy | 3 | 2011 | 18 | 0.910 |
Why?
| | Thiazolidinediones | 5 | 2016 | 146 | 0.720 |
Why?
| | Basal Metabolism | 2 | 2011 | 50 | 0.700 |
Why?
| | Subcutaneous Fat | 2 | 2011 | 78 | 0.690 |
Why?
| | HIV Protease Inhibitors | 4 | 2011 | 64 | 0.590 |
Why?
| | Energy Intake | 2 | 2011 | 445 | 0.590 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 3 | 2013 | 43 | 0.550 |
Why?
| | Adiponectin | 4 | 2016 | 224 | 0.520 |
Why?
| | Leptin | 2 | 2007 | 228 | 0.480 |
Why?
| | Starvation | 1 | 2013 | 24 | 0.470 |
Why?
| | Anorexia Nervosa | 1 | 2013 | 74 | 0.440 |
Why?
| | Adipocytes | 2 | 2006 | 195 | 0.440 |
Why?
| | Organic Anion Transporters | 2 | 2011 | 19 | 0.440 |
Why?
| | Adaptation, Physiological | 2 | 2013 | 501 | 0.420 |
Why?
| | Body Fat Distribution | 1 | 2011 | 45 | 0.400 |
Why?
| | Nutritional Requirements | 1 | 2011 | 74 | 0.400 |
Why?
| | Polymorphism, Genetic | 4 | 2013 | 641 | 0.390 |
Why?
| | Adipose Tissue, Brown | 1 | 2011 | 71 | 0.380 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2012 | 80 | 0.370 |
Why?
| | HIV | 2 | 2011 | 209 | 0.370 |
Why?
| | Adipose Tissue | 4 | 2012 | 595 | 0.350 |
Why?
| | Absorptiometry, Photon | 1 | 2009 | 226 | 0.330 |
Why?
| | Body Composition | 6 | 2013 | 644 | 0.320 |
Why?
| | Health | 1 | 2008 | 80 | 0.320 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2011 | 296 | 0.310 |
Why?
| | Calorimetry, Indirect | 4 | 2011 | 72 | 0.310 |
Why?
| | Body Temperature Regulation | 1 | 2007 | 72 | 0.300 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2006 | 258 | 0.290 |
Why?
| | Caloric Restriction | 1 | 2007 | 91 | 0.280 |
Why?
| | Anti-HIV Agents | 3 | 2012 | 662 | 0.270 |
Why?
| | Adult | 21 | 2016 | 31324 | 0.270 |
Why?
| | Body Mass Index | 6 | 2013 | 2074 | 0.250 |
Why?
| | Blood Glucose | 3 | 2016 | 1936 | 0.240 |
Why?
| | Hypoglycemic Agents | 4 | 2016 | 1031 | 0.240 |
Why?
| | Glucose Tolerance Test | 4 | 2011 | 361 | 0.240 |
Why?
| | Middle Aged | 17 | 2016 | 27510 | 0.230 |
Why?
| | Metabolic Syndrome | 3 | 2016 | 392 | 0.230 |
Why?
| | Lipid Metabolism | 1 | 2006 | 473 | 0.220 |
Why?
| | Pancreatitis | 1 | 2003 | 105 | 0.210 |
Why?
| | Dietary Carbohydrates | 1 | 2003 | 157 | 0.210 |
Why?
| | Male | 22 | 2016 | 57474 | 0.210 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2003 | 360 | 0.190 |
Why?
| | Regression Analysis | 3 | 2011 | 984 | 0.170 |
Why?
| | Female | 19 | 2016 | 61261 | 0.170 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2013 | 387 | 0.160 |
Why?
| | Body Weight | 4 | 2016 | 923 | 0.160 |
Why?
| | Humans | 24 | 2016 | 118251 | 0.150 |
Why?
| | Proteins | 1 | 2003 | 935 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2013 | 4521 | 0.140 |
Why?
| | Cytochrome P-450 CYP2C8 | 3 | 2013 | 15 | 0.140 |
Why?
| | Lectins | 1 | 2016 | 49 | 0.140 |
Why?
| | Drug Therapy, Combination | 3 | 2012 | 964 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2013 | 3156 | 0.130 |
Why?
| | CD4 Lymphocyte Count | 3 | 2010 | 261 | 0.130 |
Why?
| | Ritonavir | 2 | 2012 | 70 | 0.130 |
Why?
| | HIV-1 | 3 | 2012 | 772 | 0.120 |
Why?
| | Gemfibrozil | 1 | 2013 | 10 | 0.110 |
Why?
| | Heptanoic Acids | 1 | 2013 | 62 | 0.110 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 44 | 0.110 |
Why?
| | Pyrazines | 1 | 2013 | 72 | 0.110 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2006 | 2159 | 0.110 |
Why?
| | Hypolipidemic Agents | 1 | 2013 | 86 | 0.110 |
Why?
| | Resistin | 2 | 2010 | 13 | 0.100 |
Why?
| | Pravastatin | 1 | 2011 | 29 | 0.100 |
Why?
| | Wasting Syndrome | 1 | 2011 | 11 | 0.100 |
Why?
| | Area Under Curve | 2 | 2013 | 293 | 0.100 |
Why?
| | Pyrroles | 1 | 2013 | 188 | 0.100 |
Why?
| | Triazoles | 1 | 2013 | 128 | 0.100 |
Why?
| | Tomography | 1 | 2011 | 23 | 0.100 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 187 | 0.100 |
Why?
| | Torso | 1 | 2011 | 29 | 0.100 |
Why?
| | Thermogenesis | 1 | 2011 | 43 | 0.100 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2011 | 113 | 0.100 |
Why?
| | Uridine | 1 | 2010 | 30 | 0.100 |
Why?
| | Lactation | 1 | 2011 | 156 | 0.090 |
Why?
| | Coinfection | 1 | 2011 | 119 | 0.090 |
Why?
| | Glucose Intolerance | 1 | 2011 | 139 | 0.090 |
Why?
| | Pilot Projects | 2 | 2011 | 1405 | 0.090 |
Why?
| | Leg | 1 | 2011 | 234 | 0.090 |
Why?
| | Triglycerides | 2 | 2011 | 515 | 0.090 |
Why?
| | Chemokine CXCL5 | 1 | 2008 | 11 | 0.080 |
Why?
| | Sulfonamides | 1 | 2011 | 444 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2011 | 3169 | 0.080 |
Why?
| | Cytokines | 1 | 2016 | 1880 | 0.080 |
Why?
| | Chemokine CCL2 | 1 | 2008 | 124 | 0.080 |
Why?
| | Chronic Disease | 1 | 2013 | 1630 | 0.080 |
Why?
| | Genotype | 2 | 2013 | 1870 | 0.080 |
Why?
| | Postprandial Period | 1 | 2007 | 96 | 0.070 |
Why?
| | Drug Interactions | 3 | 2013 | 351 | 0.070 |
Why?
| | Pulmonary Gas Exchange | 1 | 2007 | 117 | 0.070 |
Why?
| | Insulin Resistance | 3 | 2010 | 1167 | 0.070 |
Why?
| | Glyburide | 1 | 2006 | 36 | 0.070 |
Why?
| | 3T3-L1 Cells | 1 | 2006 | 35 | 0.070 |
Why?
| | Viral Load | 2 | 2010 | 406 | 0.070 |
Why?
| | Prevalence | 1 | 2011 | 2321 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2057 | 0.060 |
Why?
| | Eating | 1 | 2007 | 366 | 0.060 |
Why?
| | Cohort Studies | 2 | 2013 | 5078 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2007 | 1288 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2016 | 1683 | 0.060 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 38 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 939 | 0.060 |
Why?
| | Adolescent | 3 | 2011 | 18364 | 0.060 |
Why?
| | Waist Circumference | 2 | 2016 | 130 | 0.060 |
Why?
| | Cell Survival | 1 | 2006 | 1045 | 0.050 |
Why?
| | Metformin | 1 | 2006 | 293 | 0.050 |
Why?
| | Young Adult | 2 | 2013 | 10731 | 0.050 |
Why?
| | Cross-Over Studies | 2 | 2013 | 456 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 6368 | 0.050 |
Why?
| | Acute Disease | 1 | 2003 | 933 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2003 | 935 | 0.050 |
Why?
| | Pregnancy | 1 | 2011 | 5671 | 0.040 |
Why?
| | Kinetics | 1 | 2003 | 1623 | 0.040 |
Why?
| | Lipids | 2 | 2016 | 591 | 0.040 |
Why?
| | Hyperlipoproteinemias | 1 | 1998 | 6 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2006 | 1746 | 0.040 |
Why?
| | RNA, Viral | 1 | 2001 | 568 | 0.040 |
Why?
| | Sleep | 1 | 2003 | 650 | 0.040 |
Why?
| | Blood Pressure | 2 | 2016 | 1656 | 0.040 |
Why?
| | Apoptosis | 1 | 2006 | 2461 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2016 | 56 | 0.030 |
Why?
| | Diet | 1 | 2003 | 1143 | 0.030 |
Why?
| | United States | 1 | 2011 | 12488 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 753 | 0.030 |
Why?
| | Sitagliptin Phosphate | 1 | 2013 | 30 | 0.030 |
Why?
| | Biotransformation | 1 | 2013 | 52 | 0.030 |
Why?
| | Dideoxynucleosides | 1 | 2012 | 20 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2013 | 111 | 0.030 |
Why?
| | Half-Life | 1 | 2013 | 147 | 0.030 |
Why?
| | Benzoxazines | 1 | 2012 | 28 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2012 | 80 | 0.030 |
Why?
| | Atazanavir Sulfate | 1 | 2012 | 41 | 0.030 |
Why?
| | Lamivudine | 1 | 2012 | 59 | 0.030 |
Why?
| | Alkynes | 1 | 2012 | 56 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2013 | 194 | 0.030 |
Why?
| | Organophosphonates | 1 | 2012 | 94 | 0.030 |
Why?
| | Darunavir | 1 | 2011 | 17 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2012 | 136 | 0.030 |
Why?
| | Emtricitabine | 1 | 2012 | 146 | 0.030 |
Why?
| | Drug Combinations | 1 | 2012 | 291 | 0.030 |
Why?
| | Gene Frequency | 1 | 2013 | 511 | 0.030 |
Why?
| | Tenofovir | 1 | 2012 | 200 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 1937 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2013 | 355 | 0.020 |
Why?
| | Adenine | 1 | 2012 | 222 | 0.020 |
Why?
| | Oligopeptides | 1 | 2012 | 250 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 9319 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 474 | 0.020 |
Why?
| | Cholesterol | 1 | 2011 | 375 | 0.020 |
Why?
| | Mice | 1 | 2006 | 15446 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 436 | 0.020 |
Why?
| | Lipoproteins | 1 | 2010 | 163 | 0.020 |
Why?
| | Mitochondria | 1 | 2012 | 785 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2003 | 12929 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2008 | 364 | 0.020 |
Why?
| | Medication Adherence | 1 | 2010 | 554 | 0.020 |
Why?
| | Prospective Studies | 1 | 2016 | 6443 | 0.020 |
Why?
| | Animals | 1 | 2006 | 33152 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4178 | 0.010 |
Why?
| | Quality of Life | 1 | 2010 | 2355 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 3567 | 0.010 |
Why?
| | Retinoids | 1 | 1998 | 32 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 1795 | 0.010 |
Why?
| | Steroids | 1 | 1998 | 153 | 0.010 |
Why?
| | Parenteral Nutrition | 1 | 1998 | 92 | 0.010 |
Why?
| | Antihypertensive Agents | 1 | 1998 | 436 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 1998 | 682 | 0.010 |
Why?
|
|
Kosmiski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|